MTOR Signaling inhibition modulates macrophage/microglia-mediated neuroinflammation and secondary injury via regulatory T cells after focal ischemia

Journal of Immunology

Volumn 192, Issue 12, 2014, Pages 6009-6019

  Xie, Luokun ^a   Sun, Fen ^a   Wang, Jixian ^a,b   Mao, Xiao Ou ^c   Xie, Lin ^c   Yang, Shao Hua ^a   Su, Dong Ming ^a   Simpkins, James W ^a,d   Greenberg, David A ^c   Jin, Kunlin ^a  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

^d WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN ISCHEMIA; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG RESPONSE; ENZYME INHIBITION; GRANULOCYTE; IMMUNE RESPONSE; MACROPHAGE; MALE; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; POLARIZATION; PRIORITY JOURNAL; RAT; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; T CELL DEPLETION; TASK PERFORMANCE; TUMOR VOLUME;

ANIMALS; BRAIN ISCHEMIA; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; MACROPHAGES; MALE; MICROGLIA; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; SIGNAL TRANSDUCTION; SIROLIMUS; STROKE; T-LYMPHOCYTES, REGULATORY; TOR SERINE-THREONINE KINASES;

EID: 84902203576     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1303492     Document Type: Article

References (72)

1. Go, A. S., D. Mozaffarian, V. L. Roger, E. J. Benjamin, J. D. Berry, M. J. Blaha, S. Dai, E. S. Ford, C. S. Fox, S. Franco, et al. 2014. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation 129:e28-e292.
2. Brott, T., and J. Bogousslavsky. 2000. Treatment of acute ischemic stroke. N. Engl. J. Med. 343:710-722.
3. Wang, Y., Z. Zhang, N. Chow, T. P. Davis, J. H. Griffin, M. Chopp, and B. V. Zlokovic. 2012. An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents. Stroke 43:2444-2449.
4. Wechsler, L. R., and T. G. Jovin. 2012. Intravenous recombinant tissue-type plasminogen activator in the extended time window and the US Food and Drug Administration: confused about the time. Stroke 43:2517-2519.
5. Jin, R., G. Yang, and G. Li. 2010. Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. J. Leukoc. Biol. 87:779-789.
6. Sughrue, M. E., A. Mehra, E. S. Connolly, Jr., and A. L. D'Ambrosio. 2004. Anti-adhesion molecule strategies as potential neuroprotective agents in cerebral ischemia: a critical review of the literature. Inflamm. Res. 53:497-508.
7. Wiederrecht, G. J., C. J. Sabers, G. J. Brunn, M. M. Martin, F. J. Dumont, and R. T. Abraham. 1995. Mechanism of action of rapamycin: new insights into the regulation of G1-phase progression in eukaryotic cells. Prog. Cell Cycle Res. 1:53-71.
8. Laplante, M., and D. M. Sabatini. 2009. mTOR signaling at a glance. J. Cell Sci. 122:3589-3594.
9. Thomson, A. W., H. R. Turnquist, and G. Raimondi. 2009. Immunoregulatory functions of mTOR inhibition. Nat. Rev. Immunol. 9:324-337.
10. Chauhan, A., U. Sharma, N. R. Jagannathan, K. H. Reeta, and Y. K. Gupta. 2011. Rapamycin protects against middle cerebral artery occlusion induced focal cerebral ischemia in rats. Behav. Brain Res. 225:603-609.
11. Carloni, S., S. Girelli, C. Scopa, G. Buonocore, M. Longini, and W. Balduini. 2010. Activation of autophagy and Akt/CREB signaling play an equivalent role in the neuroprotective effect of rapamycin in neonatal hypoxia-ischemia. Autophagy 6:366-377.
12. Fletcher, L., T. M. Evans, L. T. Watts, D. F. Jimenez, and M. Digicaylioglu. 2013. Rapamycin treatment improves neuron viability in an in vitro model of stroke. PLoS One 8:e68281.
13. Jin, K., M. Minami, J. Q. Lan, X. O. Mao, S. Batteur, R. P. Simon, and D. A. Greenberg. 2001. Neurogenesis in dentate subgranular zone and rostral subventricular zone after focal cerebral ischemia in the rat. Proc. Natl. Acad. Sci. USA 98:4710-4715.
14. Swanson, R. A., M. T. Morton, G. Tsao-Wu, R. A. Savalos, C. Davidson, and F. R. Sharp. 1990. A semiautomated method for measuring brain infarct volume. J. Cereb. Blood Flow Metab. 10:290-293.
15. Sun, F., L. Xie, X. Mao, J. Hill, D. A. Greenberg, and K. Jin. 2012. Effect of a contralateral lesion on neurological recovery from stroke in rats. Restor. Neurol. Neurosci. 30:491-495.
16. Shichita, T., Y. Sugiyama, H. Ooboshi, H. Sugimori, R. Nakagawa, I. Takada, T. Iwaki, Y. Okada, M. Iida, D. J. Cua, et al. 2009. Pivotal role of cerebral interleukin-17-producing gammadeltaT cells in the delayed phase of ischemic brain injury. Nat. Med. 15:946-950.
17. Ghiringhelli, F., N. Larmonier, E. Schmitt, A. Parcellier, D. Cathelin, C. Garrido, B. Chauffert, E. Solary, B. Bonnotte, and F. Martin. 2004. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 34:336-344.
18. Ghiringhelli, F., P. E. Puig, S. Roux, A. Parcellier, E. Schmitt, E. Solary, G. Kroemer, F. Martin, B. Chauffert, and L. Zitvogel. 2005. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4 +CD25+ regulatory T cell proliferation. J. Exp. Med. 202:919-929.
19. Hill, J. J., K. Jin, X. O. Mao, L. Xie, and D. A. Greenberg. 2012. Intracerebral chondroitinase ABC and heparan sulfate proteoglycan glypican improve outcome from chronic stroke in rats. Proc. Natl. Acad. Sci. USA 109:9155-9160.
20. Wang, X., T. L. Yue, F. C. Barone, R. F. White, R. C. Gagnon, and G. Z. Feuerstein. 1994. Concomitant cortical expression of TNF-alpha and IL-1 beta mRNAs follows early response gene expression in transient focal ischemia. Mol. Chem. Neuropathol. 23:103-114.
21. Liu, T., P. C. McDonnell, P. R. Young, R. F. White, A. L. Siren, J. M. Hallenbeck, F. C. Barone, and G. Z. Feurestein. 1993. Interleukin-1 beta mRNA expression in ischemic rat cortex. Stroke 24:1746-1750; discussion 1750-1741.
22. Wiessner, C., J. Gehrmann, D. Lindholm, R. Töpper, G. W. Kreutzberg, and K. A. Hossmann. 1993. Expression of transforming growth factor-beta 1 and interleukin-1 beta mRNA in rat brain following transient forebrain ischemia. Acta Neuropathol. 86:439-446.
23. Liu, T., R. K. Clark, P. C. McDonnell, P. R. Young, R. F. White, F. C. Barone, and G. Z. Feuerstein. 1994. Tumor necrosis factor-alpha expression in ischemic neurons. Stroke 25:1481-1488.
24. Wang, X., T. L. Yue, F. C. Barone, and G. Z. Feuerstein. 1995. Monocyte chemoattractant protein-1 messenger RNA expression in rat ischemic cortex. Stroke 26:661-665, discussion 665-666.
25. Kim, J. S., S. C. Gautam, M. Chopp, C. Zaloga, M. L. Jones, P. A. Ward, and K. M. Welch. 1995. Expression of monocyte chemoattractant protein-1 and macrophage inflammatory protein-1 after focal cerebral ischemia in the rat. J. Neuroimmunol. 56:127-134.
26. Pantoni, L., C. Sarti, and D. Inzitari. 1998. Cytokines and cell adhesion molecules in cerebral ischemia: experimental bases and therapeutic perspectives. Arterioscler. Thromb. Vasc. Biol. 18:503-513.
27. Gelderblom, M., F. Leypoldt, K. Steinbach, D. Behrens, C. U. Choe, D. A. Siler, T. V. Arumugam, E. Orthey, C. Gerloff, E. Tolosa, and T. Magnus. 2009. Temporal and spatial dynamics of cerebral immune cell accumulation in stroke. Stroke 40:1849-1857.
28. Baker, A. K., R. Wang, N. Mackman, and J. P. Luyendyk. 2009. Rapamycin enhances LPS induction of tissue factor and tumor necrosis factor-alpha expression in macrophages by reducing IL-10 expression. Mol. Immunol. 46:2249-2255.
29. Mercalli, A., I. Calavita, E. Dugnani, A. Citro, E. Cantarelli, R. Nano, R. Melzi, P. Maffi, A. Secchi, V. Sordi, and L. Piemonti. 2013. Rapamycin unbalances the polarization of human macrophages to M1. Immunology 140:179-190.
30. Penido, C., M. F. Costa, M. C. Souza, K. A. Costa, A. L. Candéa, C. F. Benjamim, and Md. Henriques. 2008. Involvement of CC chemokines in gammadelta T lymphocyte trafficking during allergic inflammation: the role of CCL2/CCR2 pathway. Int. Immunol. 20:129-139.
31. Lança, T., M. F. Costa, N. Gonçalves-Sousa, M. Rei, A. R. Grosso, C. Penido, and B. Silva-Santos. 2013. Protective role of the inflammatory CCR2/CCL2 chemokine pathway through recruitment of type 1 cytotoxic gd T lymphocytes to tumor beds. J. Immunol. 190:6673-6680.
32. Biswas, S. K., and A. Mantovani. 2010. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 11:889-896.
33. Murray, P. J., and T. A. Wynn. 2011. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 11:723-737.
34. Wang, X., W. Wang, J. Xu, and Q. Le. 2013. Effect of rapamycin and interleukin-2 on regulatory CD4+CD25+Foxp3+ T cells in mice after allogenic corneal transplantation. Transplant. Proc. 45:528-537.
35. Wang, Y., G. Camirand, Y. Lin, M. Froicu, S. Deng, W. D. Shlomchik, F. G. Lakkis, and D. M. Rothstein. 2011. Regulatory T cells require mammalian target of rapamycin signaling to maintain both homeostasis and alloantigendriven proliferation in lymphocyte-replete mice. J. Immunol. 186:2809-2818.
36. Shin, H. J., J. Baker, D. B. Leveson-Gower, A. T. Smith, E. I. Sega, and R. S. Negrin. 2011. Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells. Blood 118:2342-2350.
37. Liesz, A., E. Suri-Payer, C. Veltkamp, H. Doerr, C. Sommer, S. Rivest, T. Giese, and R. Veltkamp. 2009. Regulatory T cells are key cerebroprotective immunomodulators in acute experimental stroke. Nat. Med. 15:192-199.
38. Thornton, A. M., P. E. Korty, D. Q. Tran, E. A. Wohlfert, P. E. Murray, Y. Belkaid, and E. M. Shevach. 2010. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J. Immunol. 184:3433-3441.
39. Yilmaz, G., and D. N. Granger. 2010. Leukocyte recruitment and ischemic brain injury. Neuromolecular Med. 12:193-204.
40. Wang, Q., X. N. Tang, and M. A. Yenari. 2007. The inflammatory response in stroke. J. Neuroimmunol. 184:53-68.
41. Kleinschnitz, C., N. Schwab, P. Kraft, I. Hagedorn, A. Dreykluft, T. Schwarz, M. Austinat, B. Nieswandt, H. Wiendl, and G. Stoll. 2010. Early detrimental Tcell effects in experimental cerebral ischemia are neither related to adaptive immunity nor thrombus formation. Blood 115:3835-3842.
42. Iadecola, C., and J. Anrather. 2011. The immunology of stroke: from mechanisms to translation. Nat. Med. 17:796-808.
43. Kleinschnitz, C., P. Kraft, A. Dreykluft, I. Hagedorn, K. Göbel, M. K. Schuhmann, F. Langhauser, X. Helluy, T. Schwarz, S. Bittner, et al. 2013. Regulatory T cells are strong promoters of acute ischemic stroke in mice by inducing dysfunction of the cerebral microvasculature. Blood 121:679-691.
44. Ren, X., K. Akiyoshi, A. A. Vandenbark, P. D. Hurn, and H. Offner. 2011. CD4 +FoxP3+ regulatory T-cells in cerebral ischemic stroke. Metab. Brain Dis. 26:87-90.
45. Wohler, J. E., S. S. Smith, K. R. Zinn, D. C. Bullard, and S. R. Barnum. 2009. Gammadelta T cells in EAE: early trafficking events and cytokine requirements. Eur. J. Immunol. 39:1516-1526.
46. Lakhan, S. E., A. Kirchgessner, and M. Hofer. 2009. Inflammatory mechanisms in ischemic stroke: therapeutic approaches. J. Transl. Med. 7:97.
47. Frenkel, D., Z. Huang, R. Maron, D. N. Koldzic, M. A. Moskowitz, and H. L. Weiner. 2005. Neuroprotection by IL-10-producing MOG CD4+ T cells following ischemic stroke. J. Neurol. Sci. 233:125-132.
48. Strle, K., J. H. Zhou, W. H. Shen, S. R. Broussard, R. W. Johnson, G. G. Freund, R. Dantzer, and K. W. Kelley. 2001. Interleukin-10 in the brain. Crit. Rev. Immunol. 21:427-449.
49. Lee, J. H., J. P. Lydon, and C. H. Kim. 2012. Progesterone suppresses the mTOR pathway and promotes generation of induced regulatory T cells with increased stability. Eur. J. Immunol. 42:2683-2696.
50. Yurchenko, E., M. T. Shio, T. C. Huang, M. Da Silva Martins, M. Szyf, M. K. Levings, M. Olivier, and C. A. Piccirillo. 2012. Inflammation-driven reprogramming of CD4+ Foxp3+ regulatory T cells into pathogenic Th1/Th17 T effectors is abrogated by mTOR inhibition in vivo. PLoS One 7:e35572.
51. Battaglia, M., A. Stabilini, and E. Tresoldi. 2012. Expanding human T regulatory cells with the mTOR-inhibitor rapamycin. Methods Mol. Biol. 821:279-293.
52. Delgoffe, G. M., T. P. Kole, Y. Zheng, P. E. Zarek, K. L. Matthews, B. Xiao, P. F. Worley, S. C. Kozma, and J. D. Powell. 2009. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 30:832-844.
53. Zhang, P., S. K. Tey, M. Koyama, R. D. Kuns, S. D. Olver, K. E. Lineburg, M. Lor, B. E. Teal, N. C. Raffelt, J. Raju, et al. 2013. Induced regulatory T cells promote tolerance when stabilized by rapamycin and IL-2 in vivo. J. Immunol. 191:5291-5303.
54. Zhang, W., D. Zhang, M. Shen, Y. Liu, Y. Tian, A. W. Thomson, W. P. Lee, and X. X. Zheng. 2010. Combined administration of a mutant TGF-beta1/Fc and rapamycin promotes induction of regulatory T cells and islet allograft tolerance. J. Immunol. 185:4750-4759.
55. Park, Y., H. S. Jin, J. Lopez, C. Elly, G. Kim, M. Murai, M. Kronenberg, and Y. C. Liu. 2013. TSC1 regulates the balance between effector and regulatory T cells. J. Clin. Invest. 123:5165-5178.
56. Haxhinasto, S., D. Mathis, and C. Benoist. 2008. The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells. J. Exp. Med. 205:565-574.
57. Collison, L. W., C. J. Workman, T. T. Kuo, K. Boyd, Y. Wang, K. M. Vignali, R. Cross, D. Sehy, R. S. Blumberg, and D. A. Vignali. 2007. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450:566-569.
58. Tsuji-Takayama, K., M. Suzuki, M. Yamamoto, A. Harashima, A. Okochi, T. Otani, T. Inoue, A. Sugimoto, T. Toraya, M. Takeuchi, et al. 2008. The production of IL-10 by human regulatory T cells is enhanced by IL-2 through a STAT5-responsive intronic enhancer in the IL-10 locus. J. Immunol. 181:3897-3905.
59. Tsuji-Takayama, K., M. Suzuki, M. Yamamoto, A. Harashima, A. Okochi, T. Otani, T. Inoue, A. Sugimoto, R. Motoda, F. Yamasaki, et al. 2008. IL-2 activation of STAT5 enhances production of IL-10 from human cytotoxic regulatory T cells, HOZOT. Exp. Hematol. 36:181-192.
60. Brandenburg, S., T. Takahashi, M. De La Rosa, M. Janke, G. Karsten, T. Muzzulini, Z. Orinska, S. Bulfone-Paus, and A. Scheffold. 2008. IL-2 induces in vivo suppression by CD4 (+) CD25 (+) Foxp3 (+) regulatory T cells. Eur. J. Immunol. 38:1643-1653.
61. Dodge, I. L., G. Demirci, T. B. Strom, and X. C. Li. 2000. Rapamycin induces transforming growth factor-beta production by lymphocytes. Transplantation 70:1104-1106.
62. Wang, X., W. Wang, J. Xu, J. Hong, and Q. Le. 2013. Pretreatment of rapamycin before allogenic corneal transplant promotes graft survival through increasing CD4 (+) CD25 (+) Foxp3 (+) regulatory T cells. Exp. Clin. Transplant. 11:56-62.
63. Wang, C., T. Yi, L. Qin, R. A. Maldonado, U. H. Von Andrian, S. Kulkarni, G. Tellides, and J. S. Pober. 2013. Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells. J. Clin. Invest. 123:1677-1693.
64. Turnquist, H. R., G. Raimondi, A. F. Zahorchak, R. T. Fischer, Z. Wang, and A. W. Thomson. 2007. Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J. Immunol. 178:7018-7031.
65. Hu, X., P. Li, Y. Guo, H. Wang, R. K. Leak, S. Chen, Y. Gao, and J. Chen. 2012. Microglia/macrophage polarization dynamics reveal novel mechanism of injury expansion after focal cerebral ischemia. Stroke 43:3063-3070.
66. Perego, C., S. Fumagalli, and M. G. De Simoni. 2011. Temporal pattern of expression and colocalization of microglia/macrophage phenotype markers following brain ischemic injury in mice. J. Neuroinflammation 8:174.
67. Lambertsen, K. L., K. Biber, and B. Finsen. 2012. Inflammatory cytokines in experimental and human stroke. J. Cereb. Blood Flow Metab. 32:1677-1698.
68. Shih, A. Y., H. B. Fernandes, F. Y. Choi, M. G. Kozoriz, Y. Liu, P. Li, C. M. Cowan, and A. Klegeris. 2006. Policing the police: astrocytes modulate microglial activation. J. Neurosci. 26:3887-3888.
69. Viscomi, M. T., M. D'Amelio, V. Cavallucci, L. Latini, E. Bisicchia, F. Nazio, F. Fanelli, M. Maccarrone, S. Moreno, F. Cecconi, and M. Molinari. 2012. Stimulation of autophagy by rapamycin protects neurons from remote degeneration after acute focal brain damage. Autophagy 8:222-235.
70. Lisi, L., P. Navarra, D. L. Feinstein, and C. Dello Russo. 2011. The mTOR kinase inhibitor rapamycin decreases iNOS mRNA stability in astrocytes. J. Neuroinflammation 8:1.
71. Codeluppi, S., C. I. Svensson, M. P. Hefferan, F. Valencia, M. D. Silldorff, M. Oshiro, M. Marsala, and E. B. Pasquale. 2009. The Rheb-mTOR pathway is upregulated in reactive astrocytes of the injured spinal cord. J. Neurosci. 29:1093-1104.
72. Banerjee, S., S. M. Gianino, F. Gao, U. Christians, and D. H. Gutmann. 2011. Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes. Mol. Cancer Ther. 10:279-291